{
    "xml": "<topic id=\"PHP2273\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/clozapine\" basename=\"clozapine\" title=\"CLOZAPINE\">\n<title>CLOZAPINE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_364\" namespace=\"/interactions/list-of-drug-interactions/antipsychotics/clozapine\">Clozapine</xref>\n</p>\n<data name=\"vtmid\">96221003</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_358387308\" title=\"Antipsychotics (second-generation)\">Antipsychotics (second-generation)</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34569\" title=\"ANTIPSYCHOTIC DRUGS\" namespace=\"/drug-classes/antipsychotic-drugs\">ANTIPSYCHOTIC DRUGS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">   </data>\n</data>\r\n</body>\n<topic id=\"PHP69136\" outputclass=\"drugAction\" rev=\"1.10\" parent=\"/drugs/clozapine\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>\n<b>Clozapine</b> is a dopamine D<sub>1</sub>, dopamine D<sub>2</sub>, 5-HT<sub>2A</sub>, alpha<sub>1</sub>-adrenoceptor, and muscarinic-receptor antagonist.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69051\" outputclass=\"indicationsAndDose\" rev=\"1.25\" parent=\"/drugs/clozapine\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Schizophrenia in patients unresponsive to, or intolerant of, conventional antipsychotic drugs</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult 18&#8211;59 years</p>\n<p>12.5&#8239;mg 1&#8211;2 times a day for day 1, then 25&#8211;50&#8239;mg for day 2, then increased, if tolerated, in steps of 25&#8211;50&#8239;mg daily, dose to be increased gradually over 14&#8211;21 days, increased to up to 300&#8239;mg daily in divided doses, larger dose to be taken at night, up to 200&#8239;mg daily may be taken as a single dose at bedtime; increased in steps of 50&#8211;100&#8239;mg 1&#8211;2 times a week if required, it is preferable to increase once a week; usual dose 200&#8211;450&#8239;mg daily, restarting after interval of more than 48 hours, 12.5&#8239;mg once or twice on first day (but may be feasible to increase more quickly than on initiation)&#8212;extreme caution if previous respiratory or cardiac arrest with initial dosing; maximum 900&#8239;mg per day.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult 60 years and over</p>\n<p>12.5&#8239;mg once daily for day 1, then increased to 25&#8211;37.5&#8239;mg for day 2, then increased, if tolerated, in steps of up to 25&#8239;mg daily, dose to be increased gradually over 14&#8211;21 days, increased to up to 300&#8239;mg daily in divided doses, larger dose at to be taken night, up to 200&#8239;mg daily may be taken as a single dose at bedtime; increased in steps of 50&#8211;100&#8239;mg 1&#8211;2 times a week if required, it is preferable to increase once a week; usual dose 200&#8211;450&#8239;mg daily, restarting after interval of more than 48 hours, 12.5&#8239;mg once or twice on first day (but may be feasible to increase more quickly than on initiation)&#8212;extreme caution if previous respiratory or cardiac arrest with initial dosing; maximum 900&#8239;mg per day.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Psychosis in Parkinson's disease</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>12.5&#8239;mg once daily, dose to be taken at bedtime, then increased in steps of 12.5&#8239;mg up to twice weekly, adjusted according to response; usual dose 25&#8211;37.5&#8239;mg once daily, dose to be taken at bedtime; increased in steps of 12.5&#8239;mg once weekly, this applies only in exceptional cases, increased if necessary up to 100&#8239;mg daily in 1&#8211;2 divided doses; Usual maximum 50&#8239;mg/24 hours.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"doseAdjustments\">\n<title>Dose adjustments due to interactions</title>\n<sectiondiv>\n<p>Dose adjustment may be necessary if smoking started or stopped during treatment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69170\" outputclass=\"contraindications\" rev=\"1.10\" parent=\"/drugs/clozapine\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Alcoholic and toxic psychoses</ph>; <ph outputclass=\"contraindication\">bone-marrow disorders</ph>; <ph outputclass=\"contraindication\">coma</ph>; <ph outputclass=\"contraindication\">drug intoxication</ph>; <ph outputclass=\"contraindication\">history of agranulocytosis</ph>; <ph outputclass=\"contraindication\">history of circulatory collapse</ph>; <ph outputclass=\"contraindication\">history of neutropenia</ph>; <ph outputclass=\"contraindication\">paralytic ileus</ph>; <ph outputclass=\"contraindication\">severe cardiac disorders (e.g. myocarditis)</ph>; <ph outputclass=\"contraindication\">severe CNS depression</ph>; <ph outputclass=\"contraindication\">uncontrolled epilepsy</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP68382\" outputclass=\"cautions\" rev=\"1.17\" parent=\"/drugs/clozapine\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Age over 60 years</ph>; <ph outputclass=\"caution\">prostatic hypertrophy</ph>; <ph outputclass=\"caution\">susceptibility to angle-closure glaucoma</ph>; <ph outputclass=\"caution\">taper off other antipsychotics before starting</ph>\n</p>\n</section>\n<section outputclass=\"importantAdvice\">\n<title>Cautions, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Agranulocytosis</p>\n<p>Neutropenia and potentially fatal agranulocytosis reported. Leucocyte and differential blood counts must be normal before starting; monitor counts every week for 18 weeks then at least every 2 weeks and if clozapine continued and blood count stable after 1 year at least every 4 weeks (and 4 weeks after discontinuation); if leucocyte count below 3000&#8239;/mm<sup>3</sup> or if absolute neutrophil count below 1500&#8239;/mm<sup>3</sup> discontinue permanently and refer to haematologist. Patients who have a low white blood cell count because of benign ethnic neutropenia may be started on clozapine with the agreement of a haematologist. Avoid drugs which depress leucopoiesis; patients should report immediately symptoms of infection, especially influenza-like illness.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Myocarditis and cardiomyopathy</p>\n<p>Fatal myocarditis (most commonly in first 2 months) and cardiomyopathy reported.</p>\n<ul>\n<li>Perform physical examination and take full medical history before starting</li>\n<li>Specialist examination required if cardiac abnormalities or history of heart disease found&#8212;clozapine initiated only in absence of severe heart disease and if benefit outweighs risk</li>\n<li>Persistent tachycardia especially in first 2 months should prompt observation for other indicators for myocarditis or cardiomyopathy</li>\n<li>If myocarditis or cardiomyopathy suspected clozapine should be stopped and patient evaluated urgently by cardiologist</li>\n<li>Discontinue permanently in clozapine-induced myocarditis or cardiomyopathy</li>\n</ul>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Intestinal obstruction</p>\n<p>Impairment of intestinal peristalsis, including constipation, intestinal obstruction, faecal impaction, and paralytic ileus, (including fatal cases) reported. Clozapine should be used with caution in patients receiving drugs that may cause constipation (e.g. antimuscarinic drugs) or in those with a history of colonic disease or lower abdominal surgery. It is essential that constipation is recognised and actively treated.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69038\" outputclass=\"interactions\" rev=\"1.11\" parent=\"/drugs/clozapine\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP68989\" outputclass=\"sideEffects\" rev=\"1.15\" parent=\"/drugs/clozapine\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Anorexia</ph>; <ph outputclass=\"sideEffect\">constipation</ph>; <ph outputclass=\"sideEffect\">hypersalivation</ph>; <ph outputclass=\"sideEffect\">malaise</ph>; <ph outputclass=\"sideEffect\">speech disorders</ph>; <ph outputclass=\"sideEffect\">urinary incontinence</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Agranulocytosis</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Circulatory collapse</ph>; <ph outputclass=\"sideEffect\">dysphagia</ph>; <ph outputclass=\"sideEffect\">hepatitis</ph>; <ph outputclass=\"sideEffect\">myocarditis</ph>; <ph outputclass=\"sideEffect\">pancreatitis</ph>; <ph outputclass=\"sideEffect\">pericarditis</ph>; <ph outputclass=\"sideEffect\">pneumonia</ph>; <ph outputclass=\"sideEffect\">pulmonary aspiration</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"veryRare\">\n<p outputclass=\"title\">Very rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Cardiomyopathy</ph>; <ph outputclass=\"sideEffect\">hypercholesterolaemia</ph>; <ph outputclass=\"sideEffect\">hypertriglyceridaemia</ph>; <ph outputclass=\"sideEffect\">interstitial nephritis</ph>; <ph outputclass=\"sideEffect\">intestinal obstruction (including fatal cases)</ph>; <ph outputclass=\"sideEffect\">myocardial infarction</ph>; <ph outputclass=\"sideEffect\">obsessive compulsive disorder</ph>; <ph outputclass=\"sideEffect\">parotid gland enlargement</ph>; <ph outputclass=\"sideEffect\">respiratory depression</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Hepatic disorders</ph>; <ph outputclass=\"sideEffect\">hepatic failure</ph>; <ph outputclass=\"sideEffect\">muscle disorders</ph>; <ph outputclass=\"sideEffect\">renal failure</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Hypersalivation</p>\n<p>Hypersalivation associated with clozapine therapy can be treated with hyoscine hydrobromide [unlicensed indication], provided that the patient is not at particular risk from the additive antimuscarinic side-effects of hyoscine and clozapine.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69024\" outputclass=\"pregnancy\" parent=\"/drugs/clozapine\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Use with caution.</p>\n<p>Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.</p>\n<p>Following maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP68393\" outputclass=\"breastFeeding\" parent=\"/drugs/clozapine\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69093\" outputclass=\"hepaticImpairment\" parent=\"/drugs/clozapine\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid in symptomatic liver disease.</p>\n<p>Avoid in progressive liver disease.</p>\n<p>Avoid in hepatic failure.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"additionalMonitoringInHepaticImpairment\">\n<sectiondiv>\n<p>Monitor hepatic function regularly.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69004\" outputclass=\"renalImpairment\" parent=\"/drugs/clozapine\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid in severe impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP68951\" outputclass=\"monitoringRequirements\" parent=\"/drugs/clozapine\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Monitor leucocyte and differential blood counts. Clozapine requires differential white blood cell monitoring weekly for 18 weeks, then fortnightly for up to one year, and then monthly as part of the clozapine patient monitoring service.</p>\n<p>Close medical supervision during initiation (risk of collapse because of hypotension and convulsions).</p>\n<p>Blood lipids and weight should be measured at baseline, at 3 months (weight should be measured at frequent intervals during the first 3 months), and then yearly with antipsychotics. Patients taking clozapine require more frequent monitoring of these parameters: every 3 months for the first year, then yearly.</p>\n<p>Fasting blood glucose should be measured at baseline, at 4&#8211;6 months, and then yearly. Patients taking clozapine should have fasting blood glucose tested at baseline, after one months&#8217; treatment, then every 4&#8211;6 months.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"patientMonitoringProgrammes\">\n<sectiondiv>\n<p>Patient, prescriber, and supplying pharmacist must be registered with the appropriate Patient Monitoring Service&#8212;it takes several days to do this.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP68969\" outputclass=\"treatmentCessation\" rev=\"1.9\" parent=\"/drugs/clozapine\">\n<title>Treatment cessation</title>\n<body>\n<section>\n<sectiondiv>\n<p>On planned withdrawal reduce dose over 1&#8211;2 weeks to avoid risk of rebound psychosis. If abrupt withdrawal necessary observe patient carefully.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP68416\" outputclass=\"directionsForAdministration\" rev=\"1.11\" parent=\"/drugs/clozapine\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p>Shake oral suspension well for 90 seconds when dispensing or if visibly settled and stand for 24 hours before use; otherwise shake well for 10 seconds before use. May be diluted with water.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69016\" outputclass=\"patientAndCarerAdvice\" rev=\"1.16\" parent=\"/drugs/clozapine\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"patientResources\">\n<sectiondiv>\n<p>A patient information leaflet should be provided.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalPatientAdvice\">\n<sectiondiv>\n<p>Patients or carers should be given advice on how to administer clozapine oral suspension.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP2273-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/clozapine\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: oral solution, oral suspension</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74628\" title=\"Tablet\" namespace=\"/drugs/clozapine/tablet\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74633\" title=\"Oral suspension\" namespace=\"/drugs/clozapine/oral-suspension\">Oral suspension</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP97237\" namespace=\"/guidance/adverse-reactions-to-drugs\" title=\"Adverse reactions to drugs\" count=\"1\" rel=\"backlink\">Adverse reactions to drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78155\" namespace=\"/treatment-summaries/psychoses-and-related-disorders\" title=\"Psychoses and related disorders\" count=\"10\" rel=\"backlink\">Psychoses and related disorders</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78560\" namespace=\"/treatment-summaries/substance-dependence\" title=\"Substance dependence\" count=\"1\" rel=\"backlink\">Substance dependence</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_364\" namespace=\"/interactions/list-of-drug-interactions/antipsychotics/clozapine\" title=\"Clozapine\" count=\"1\" rel=\"link\">Clozapine</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34569\" namespace=\"/drug-classes/antipsychotic-drugs\" title=\"ANTIPSYCHOTIC DRUGS\" count=\"1\" rel=\"link\">ANTIPSYCHOTIC DRUGS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74628\" namespace=\"/drugs/clozapine/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74633\" namespace=\"/drugs/clozapine/oral-suspension\" title=\"Oral suspension\" count=\"1\" rel=\"link\">Oral suspension</xref>\n</links>\n</topic>",
    "id": "PHP2273",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/clozapine",
    "basename": "clozapine",
    "title": "CLOZAPINE",
    "interactants": [
        {
            "id": "bnf_int_364",
            "label": "Clozapine"
        }
    ],
    "vtmid": "96221003",
    "drugClassification": [
        "Antipsychotics (second-generation)"
    ],
    "inheritsFromClass": [
        "ANTIPSYCHOTIC DRUGS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Clozapine is a dopamine D1, dopamine D2, 5-HT2A, alpha1-adrenoceptor, and muscarinic-receptor antagonist.",
                "html": "<p>\n<b>Clozapine</b> is a dopamine D<sub>1</sub>, dopamine D<sub>2</sub>, 5-HT<sub>2A</sub>, alpha<sub>1</sub>-adrenoceptor, and muscarinic-receptor antagonist.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Schizophrenia in patients unresponsive to, or intolerant of, conventional antipsychotic drugs",
                        "html": "Schizophrenia in patients unresponsive to, or intolerant of, conventional antipsychotic drugs"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "12.5 mg 1&#8211;2 times a day for day 1, then 25&#8211;50 mg for day 2, then increased, if tolerated, in steps of 25&#8211;50 mg daily, dose to be increased gradually over 14&#8211;21 days, increased to up to 300 mg daily in divided doses, larger dose to be taken at night, up to 200 mg daily may be taken as a single dose at bedtime; increased in steps of 50&#8211;100 mg 1&#8211;2 times a week if required, it is preferable to increase once a week; usual dose 200&#8211;450 mg daily, restarting after interval of more than 48 hours, 12.5 mg once or twice on first day (but may be feasible to increase more quickly than on initiation)&#8212;extreme caution if previous respiratory or cardiac arrest with initial dosing; maximum 900 mg per day.",
                        "html": "<p>12.5&#8239;mg 1&#8211;2 times a day for day 1, then 25&#8211;50&#8239;mg for day 2, then increased, if tolerated, in steps of 25&#8211;50&#8239;mg daily, dose to be increased gradually over 14&#8211;21 days, increased to up to 300&#8239;mg daily in divided doses, larger dose to be taken at night, up to 200&#8239;mg daily may be taken as a single dose at bedtime; increased in steps of 50&#8211;100&#8239;mg 1&#8211;2 times a week if required, it is preferable to increase once a week; usual dose 200&#8211;450&#8239;mg daily, restarting after interval of more than 48 hours, 12.5&#8239;mg once or twice on first day (but may be feasible to increase more quickly than on initiation)&#8212;extreme caution if previous respiratory or cardiac arrest with initial dosing; maximum 900&#8239;mg per day.</p>",
                        "ageGroup": "18&#8211;59 years"
                    },
                    {
                        "textContent": "12.5 mg once daily for day 1, then increased to 25&#8211;37.5 mg for day 2, then increased, if tolerated, in steps of up to 25 mg daily, dose to be increased gradually over 14&#8211;21 days, increased to up to 300 mg daily in divided doses, larger dose at to be taken night, up to 200 mg daily may be taken as a single dose at bedtime; increased in steps of 50&#8211;100 mg 1&#8211;2 times a week if required, it is preferable to increase once a week; usual dose 200&#8211;450 mg daily, restarting after interval of more than 48 hours, 12.5 mg once or twice on first day (but may be feasible to increase more quickly than on initiation)&#8212;extreme caution if previous respiratory or cardiac arrest with initial dosing; maximum 900 mg per day.",
                        "html": "<p>12.5&#8239;mg once daily for day 1, then increased to 25&#8211;37.5&#8239;mg for day 2, then increased, if tolerated, in steps of up to 25&#8239;mg daily, dose to be increased gradually over 14&#8211;21 days, increased to up to 300&#8239;mg daily in divided doses, larger dose at to be taken night, up to 200&#8239;mg daily may be taken as a single dose at bedtime; increased in steps of 50&#8211;100&#8239;mg 1&#8211;2 times a week if required, it is preferable to increase once a week; usual dose 200&#8211;450&#8239;mg daily, restarting after interval of more than 48 hours, 12.5&#8239;mg once or twice on first day (but may be feasible to increase more quickly than on initiation)&#8212;extreme caution if previous respiratory or cardiac arrest with initial dosing; maximum 900&#8239;mg per day.</p>",
                        "ageGroup": "60 years and over"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Psychosis in Parkinson's disease",
                        "html": "Psychosis in Parkinson's disease"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "12.5 mg once daily, dose to be taken at bedtime, then increased in steps of 12.5 mg up to twice weekly, adjusted according to response; usual dose 25&#8211;37.5 mg once daily, dose to be taken at bedtime; increased in steps of 12.5 mg once weekly, this applies only in exceptional cases, increased if necessary up to 100 mg daily in 1&#8211;2 divided doses; Usual maximum 50 mg/24 hours.",
                        "html": "<p>12.5&#8239;mg once daily, dose to be taken at bedtime, then increased in steps of 12.5&#8239;mg up to twice weekly, adjusted according to response; usual dose 25&#8211;37.5&#8239;mg once daily, dose to be taken at bedtime; increased in steps of 12.5&#8239;mg once weekly, this applies only in exceptional cases, increased if necessary up to 100&#8239;mg daily in 1&#8211;2 divided doses; Usual maximum 50&#8239;mg/24 hours.</p>"
                    }
                ]
            }
        ],
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "title": "Dose adjustments due to interactions",
                "textContent": "Dose adjustment may be necessary if smoking started or stopped during treatment.",
                "html": "<p>Dose adjustment may be necessary if smoking started or stopped during treatment.</p>"
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Alcoholic and toxic psychoses",
                "html": "Alcoholic and toxic psychoses"
            },
            {
                "type": "contraindications",
                "textContent": "bone-marrow disorders",
                "html": "bone-marrow disorders"
            },
            {
                "type": "contraindications",
                "textContent": "coma",
                "html": "coma"
            },
            {
                "type": "contraindications",
                "textContent": "drug intoxication",
                "html": "drug intoxication"
            },
            {
                "type": "contraindications",
                "textContent": "history of agranulocytosis",
                "html": "history of agranulocytosis"
            },
            {
                "type": "contraindications",
                "textContent": "history of circulatory collapse",
                "html": "history of circulatory collapse"
            },
            {
                "type": "contraindications",
                "textContent": "history of neutropenia",
                "html": "history of neutropenia"
            },
            {
                "type": "contraindications",
                "textContent": "paralytic ileus",
                "html": "paralytic ileus"
            },
            {
                "type": "contraindications",
                "textContent": "severe cardiac disorders (e.g. myocarditis)",
                "html": "severe cardiac disorders (e.g. myocarditis)"
            },
            {
                "type": "contraindications",
                "textContent": "severe CNS depression",
                "html": "severe CNS depression"
            },
            {
                "type": "contraindications",
                "textContent": "uncontrolled epilepsy",
                "html": "uncontrolled epilepsy"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Age over 60 years",
                "html": "Age over 60 years"
            },
            {
                "type": "cautions",
                "textContent": "prostatic hypertrophy",
                "html": "prostatic hypertrophy"
            },
            {
                "type": "cautions",
                "textContent": "susceptibility to angle-closure glaucoma",
                "html": "susceptibility to angle-closure glaucoma"
            },
            {
                "type": "cautions",
                "textContent": "taper off other antipsychotics before starting",
                "html": "taper off other antipsychotics before starting"
            }
        ],
        "importantAdvice": [
            {
                "type": "importantAdvice",
                "title": "Agranulocytosis",
                "textContent": "Neutropenia and potentially fatal agranulocytosis reported. Leucocyte and differential blood counts must be normal before starting; monitor counts every week for 18 weeks then at least every 2 weeks and if clozapine continued and blood count stable after 1 year at least every 4 weeks (and 4 weeks after discontinuation); if leucocyte count below 3000 /mm3 or if absolute neutrophil count below 1500 /mm3 discontinue permanently and refer to haematologist. Patients who have a low white blood cell count because of benign ethnic neutropenia may be started on clozapine with the agreement of a haematologist. Avoid drugs which depress leucopoiesis; patients should report immediately symptoms of infection, especially influenza-like illness.",
                "html": "<p>Neutropenia and potentially fatal agranulocytosis reported. Leucocyte and differential blood counts must be normal before starting; monitor counts every week for 18 weeks then at least every 2 weeks and if clozapine continued and blood count stable after 1 year at least every 4 weeks (and 4 weeks after discontinuation); if leucocyte count below 3000&#8239;/mm<sup>3</sup> or if absolute neutrophil count below 1500&#8239;/mm<sup>3</sup> discontinue permanently and refer to haematologist. Patients who have a low white blood cell count because of benign ethnic neutropenia may be started on clozapine with the agreement of a haematologist. Avoid drugs which depress leucopoiesis; patients should report immediately symptoms of infection, especially influenza-like illness.</p>"
            },
            {
                "type": "importantAdvice",
                "title": "Myocarditis and cardiomyopathy",
                "textContent": "Fatal myocarditis (most commonly in first 2 months) and cardiomyopathy reported.\n\nPerform physical examination and take full medical history before starting Specialist examination required if cardiac abnormalities or history of heart disease found&#8212;clozapine initiated only in absence of severe heart disease and if benefit outweighs risk Persistent tachycardia especially in first 2 months should prompt observation for other indicators for myocarditis or cardiomyopathy If myocarditis or cardiomyopathy suspected clozapine should be stopped and patient evaluated urgently by cardiologist Discontinue permanently in clozapine-induced myocarditis or cardiomyopathy",
                "html": "<p>Fatal myocarditis (most commonly in first 2 months) and cardiomyopathy reported.</p><ul>\n<li>Perform physical examination and take full medical history before starting</li>\n<li>Specialist examination required if cardiac abnormalities or history of heart disease found&#8212;clozapine initiated only in absence of severe heart disease and if benefit outweighs risk</li>\n<li>Persistent tachycardia especially in first 2 months should prompt observation for other indicators for myocarditis or cardiomyopathy</li>\n<li>If myocarditis or cardiomyopathy suspected clozapine should be stopped and patient evaluated urgently by cardiologist</li>\n<li>Discontinue permanently in clozapine-induced myocarditis or cardiomyopathy</li>\n</ul>"
            },
            {
                "type": "importantAdvice",
                "title": "Intestinal obstruction",
                "textContent": "Impairment of intestinal peristalsis, including constipation, intestinal obstruction, faecal impaction, and paralytic ileus, (including fatal cases) reported. Clozapine should be used with caution in patients receiving drugs that may cause constipation (e.g. antimuscarinic drugs) or in those with a history of colonic disease or lower abdominal surgery. It is essential that constipation is recognised and actively treated.",
                "html": "<p>Impairment of intestinal peristalsis, including constipation, intestinal obstruction, faecal impaction, and paralytic ileus, (including fatal cases) reported. Clozapine should be used with caution in patients receiving drugs that may cause constipation (e.g. antimuscarinic drugs) or in those with a history of colonic disease or lower abdominal surgery. It is essential that constipation is recognised and actively treated.</p>"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis.",
                "html": "<p>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis.</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Anorexia",
                        "html": "Anorexia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "constipation",
                        "html": "constipation",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hypersalivation",
                        "html": "hypersalivation",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "malaise",
                        "html": "malaise",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "speech disorders",
                        "html": "speech disorders",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "urinary incontinence",
                        "html": "urinary incontinence",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Agranulocytosis",
                        "html": "Agranulocytosis",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Circulatory collapse",
                        "html": "Circulatory collapse",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "dysphagia",
                        "html": "dysphagia",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "hepatitis",
                        "html": "hepatitis",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "myocarditis",
                        "html": "myocarditis",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "pancreatitis",
                        "html": "pancreatitis",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "pericarditis",
                        "html": "pericarditis",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "pneumonia",
                        "html": "pneumonia",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "pulmonary aspiration",
                        "html": "pulmonary aspiration",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ],
                "veryRare": [
                    {
                        "type": "veryRare",
                        "textContent": "Cardiomyopathy",
                        "html": "Cardiomyopathy",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    },
                    {
                        "type": "veryRare",
                        "textContent": "hypercholesterolaemia",
                        "html": "hypercholesterolaemia",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    },
                    {
                        "type": "veryRare",
                        "textContent": "hypertriglyceridaemia",
                        "html": "hypertriglyceridaemia",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    },
                    {
                        "type": "veryRare",
                        "textContent": "interstitial nephritis",
                        "html": "interstitial nephritis",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    },
                    {
                        "type": "veryRare",
                        "textContent": "intestinal obstruction (including fatal cases)",
                        "html": "intestinal obstruction (including fatal cases)",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    },
                    {
                        "type": "veryRare",
                        "textContent": "myocardial infarction",
                        "html": "myocardial infarction",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    },
                    {
                        "type": "veryRare",
                        "textContent": "obsessive compulsive disorder",
                        "html": "obsessive compulsive disorder",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    },
                    {
                        "type": "veryRare",
                        "textContent": "parotid gland enlargement",
                        "html": "parotid gland enlargement",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    },
                    {
                        "type": "veryRare",
                        "textContent": "respiratory depression",
                        "html": "respiratory depression",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Hepatic disorders",
                        "html": "Hepatic disorders",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hepatic failure",
                        "html": "hepatic failure",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "muscle disorders",
                        "html": "muscle disorders",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "renal failure",
                        "html": "renal failure",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "title": "Hypersalivation",
                "textContent": "Hypersalivation associated with clozapine therapy can be treated with hyoscine hydrobromide [unlicensed indication], provided that the patient is not at particular risk from the additive antimuscarinic side-effects of hyoscine and clozapine.",
                "html": "<p>Hypersalivation associated with clozapine therapy can be treated with hyoscine hydrobromide [unlicensed indication], provided that the patient is not at particular risk from the additive antimuscarinic side-effects of hyoscine and clozapine.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Use with caution.\n\nExtrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.\n\nFollowing maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.",
                "html": "<p>Use with caution.</p><p>Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.</p><p>Following maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid.",
                "html": "<p>Avoid.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid in symptomatic liver disease.\n\nAvoid in progressive liver disease.\n\nAvoid in hepatic failure.",
                "html": "<p>Avoid in symptomatic liver disease.</p><p>Avoid in progressive liver disease.</p><p>Avoid in hepatic failure.</p>"
            }
        ],
        "additionalMonitoring": [
            {
                "type": "additionalMonitoring",
                "textContent": "Monitor hepatic function regularly.",
                "html": "<p>Monitor hepatic function regularly.</p>"
            }
        ]
    },
    "renalImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid in severe impairment.",
                "html": "<p>Avoid in severe impairment.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Monitor leucocyte and differential blood counts. Clozapine requires differential white blood cell monitoring weekly for 18 weeks, then fortnightly for up to one year, and then monthly as part of the clozapine patient monitoring service.\n\nClose medical supervision during initiation (risk of collapse because of hypotension and convulsions).\n\nBlood lipids and weight should be measured at baseline, at 3 months (weight should be measured at frequent intervals during the first 3 months), and then yearly with antipsychotics. Patients taking clozapine require more frequent monitoring of these parameters: every 3 months for the first year, then yearly.\n\nFasting blood glucose should be measured at baseline, at 4&#8211;6 months, and then yearly. Patients taking clozapine should have fasting blood glucose tested at baseline, after one months&#8217; treatment, then every 4&#8211;6 months.",
                "html": "<p>Monitor leucocyte and differential blood counts. Clozapine requires differential white blood cell monitoring weekly for 18 weeks, then fortnightly for up to one year, and then monthly as part of the clozapine patient monitoring service.</p><p>Close medical supervision during initiation (risk of collapse because of hypotension and convulsions).</p><p>Blood lipids and weight should be measured at baseline, at 3 months (weight should be measured at frequent intervals during the first 3 months), and then yearly with antipsychotics. Patients taking clozapine require more frequent monitoring of these parameters: every 3 months for the first year, then yearly.</p><p>Fasting blood glucose should be measured at baseline, at 4&#8211;6 months, and then yearly. Patients taking clozapine should have fasting blood glucose tested at baseline, after one months&#8217; treatment, then every 4&#8211;6 months.</p>"
            }
        ],
        "patientMonitoringProgrammes": [
            {
                "type": "patientMonitoringProgrammes",
                "textContent": "Patient, prescriber, and supplying pharmacist must be registered with the appropriate Patient Monitoring Service&#8212;it takes several days to do this.",
                "html": "<p>Patient, prescriber, and supplying pharmacist must be registered with the appropriate Patient Monitoring Service&#8212;it takes several days to do this.</p>"
            }
        ]
    },
    "treatmentCessation": {
        "treatmentCessation": [
            {
                "type": "treatmentCessation",
                "textContent": "On planned withdrawal reduce dose over 1&#8211;2 weeks to avoid risk of rebound psychosis. If abrupt withdrawal necessary observe patient carefully.",
                "html": "<p>On planned withdrawal reduce dose over 1&#8211;2 weeks to avoid risk of rebound psychosis. If abrupt withdrawal necessary observe patient carefully.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "textContent": "Shake oral suspension well for 90 seconds when dispensing or if visibly settled and stand for 24 hours before use; otherwise shake well for 10 seconds before use. May be diluted with water.",
                "html": "<p>Shake oral suspension well for 90 seconds when dispensing or if visibly settled and stand for 24 hours before use; otherwise shake well for 10 seconds before use. May be diluted with water.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "patientResources": [
            {
                "type": "patientResources",
                "textContent": "A patient information leaflet should be provided.",
                "html": "<p>A patient information leaflet should be provided.</p>"
            }
        ],
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "textContent": "Patients or carers should be given advice on how to administer clozapine oral suspension.",
                "html": "<p>Patients or carers should be given advice on how to administer clozapine oral suspension.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "oral solution",
                "oral suspension"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP74628",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP74633",
                "label": "Oral suspension",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP97237",
                "label": "Adverse reactions to drugs",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78155",
                "label": "Psychoses and related disorders",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78560",
                "label": "Substance dependence",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_364",
                "label": "Clozapine",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34569",
                "label": "ANTIPSYCHOTIC DRUGS",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP74628",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP74633",
                "label": "Oral suspension",
                "type": "medicinalForm"
            }
        ]
    }
}